Abstract
Antimicrobial resistance was associated with 4·95 million deaths worldwide in 2019.1 Although broadening access to affordable health care and sanitation are the most promising means to reduce morbidity and mortality associated with antimicrobial resistance, novel classes of antibiotics are urgently needed.2 However, low profitability means that most large pharmaceutical companies have withdrawn from antibiotic research and development. Meanwhile, reviews of compounds that remain in the research and development pipeline note that many such compounds are modifications of existing drug classes and do not constitute the molecular innovation needed to stay ahead of antimicrobial resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
